The Potential of Imlifidase 2021 International Clinical Webinar
Imlifidase specifically targets IgG and inhibits pathogenic IgG-mediated immune responses in transplant patients and patients with autoimmune disease or cancer. Imlifidase infusion has a better safety profile than plasmapheresis, and three patients in a clinical phase II trial received two doses within a 24-hour period without experiencing allergic reactions. Imlifidase is currently approved for sensitized transplant candidates in the European Union who are receiving organs from deceased donors, but it is under consideration as a treatment for patients receiving organs from living donors.
Speaker:
Angela Maldonado
PharmD – Scientific Affairs Director
Hansa BioPharma
Recorded:
Oct 27, 2021
Videos In This Series
- New Antibody Advances ❯
- The Potential of Imlifidase ❯
- Advancements in AllType FASTPlex ❯
- An Introduction to and the Evolution of the UK Living Kidney Sharing Scheme ❯
- HLA Typing by Next-Generation Sequencing (NGS) Using the AllType Fastplex Kit and the Relevance of Anti-HLA Antibody Monitoring After Kidney Transplantation ❯
- Non-HLA Antibodies: Preliminary Experience ❯
© 2023 Thermo Fisher Scientific Inc. All rights reserved.